EP0598365A1 - Agent for the treatment of an atopic eczema and other inflammatory skin diseases - Google Patents
Agent for the treatment of an atopic eczema and other inflammatory skin diseases Download PDFInfo
- Publication number
- EP0598365A1 EP0598365A1 EP93118411A EP93118411A EP0598365A1 EP 0598365 A1 EP0598365 A1 EP 0598365A1 EP 93118411 A EP93118411 A EP 93118411A EP 93118411 A EP93118411 A EP 93118411A EP 0598365 A1 EP0598365 A1 EP 0598365A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- oil
- weight
- treatment
- skin diseases
- atopic eczema
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
Definitions
- the invention relates to an agent for the treatment of atopic eczema and other inflammatory skin diseases.
- the fields of application of the invention extend to the health care, cosmetic and pharmaceutical industries.
- LTB4 leukotriene B4
- Atopic eczema BM Czarnetzki et al .: Clin. Exp. Immunol. 54 (1983) 486; K Fogh et al .: J. Allergy Clin. Immunol. 83 (1989) 68; T. Ruzicka et al: J. Invest. Dermatol. 86 (1986) 105), Psoriasis (S. Brain et al .: J. Invest Dermatol. 83 (1984) 70; K. Fogh et al .: Arch. Dermatol.
- LTB4 inflammatory mediator leukotriene B4
- glucocorticosteroids and other phospholipase A2 inhibitors or 5-lipoxygenase inhibitors are effective in treating atopic eczema, psoriasis and also contact allergic eczema (reviews: BC Bastian et al .: Dermatologist 42 (1991) 417; RDR Camp and FF Derm: J. Invest. Dermatol. 92 (1989) 789; BR Allen and SM Littlewood: Br. Med. J. 285 (1982) 1241).
- DE-A-33 25 130 describes pharmaceutical compositions for use on the skin based on essential fatty acids.
- EP-A 0 439 640 describes an agent for the therapy of inflammatory skin diseases or for the weakening of allergic, inflammatory reactions of the skin by external application of water-soluble magnesium salts, in particular magnesium chloride.
- the object of the invention is to provide medical practice with new agents which are suitable for the therapy of inflammatory skin diseases, in particular atopic eczema.
- atopic eczema and other inflammatory skin diseases consisting of an externally applicable preparation containing at least 0.5% by weight of gamma-linolenic acid and / or eicosapentaenoic acid and additionally 1 to 30% by weight of water-soluble magnesium salts.
- the concentration of the fatty acids is in a range from 0.5 to 50.0% by weight, the fatty acids being incorporated into carrier materials which can be applied to the skin.
- the concentration of magnesium is in the range of 1.0 to 30.0% by weight in the above. Backing material.
- the model of "croton oil-induced inflammatory edema” is used as an animal experiment model. It is known that the inflammation in this model primarily results from the action of LTB ((CB Archer et al .: Prostaglandins 33 (1987) 799; SE Dahlen et al .: Proc. Natl. Acad. Sci (USA) 78 (1981) 3887; M. Katori et al .: Prostaglandins 28 (1984) 617).
- mice Male animals, weight 18-25 g. Each group of animals consisted of 8 animals.
- one ear right outer and inner ear leaf of each animal was treated with 10 ⁇ l croton oil (1%, dissolved in acetone). 10 ⁇ l acetone was applied to the left ear in the same way.
- 10 ⁇ l of the fatty acids shown in Table 1 were applied alone or incorporated into a carrier medium together with MgCl2 to the right ear, and the right ear was treated with 2.5 ⁇ g of this combination or with 2.5 ⁇ g of the hydrocortisone Wolff R 0 , 5 cream treated (No. 2 and No. 3 in Table 1).
- the pure gamma-linolenic acid or oils with a natural proportion of gamma-linolenic acid or eicosapentaenoic acid are anti-inflammatory in all concentrations that can be applied to the skin in concentrations of 0.5% to 50.0%.
- ointment base is Alcoholum emulsificans non ionogenicum. In principle, however, all the usual bases for ointments, creams, lotions and gels are suitable, which are also used for external applications.
- Table 2 shows that the two individual components magnesium chloride and evening primrose oil alone in the same ointment base each show only a percentage inhibition of inflammatory edema of 37 and 30.6%, respectively.
- the combination of these two active substances according to the invention shows an inhibition percentage of 58% and thus achieves for the first time a comparable effect to that of hydrocortisone. It was not foreseeable that it would be possible to achieve such good results with the combination of the two natural and non-hazardous active substances in a disease that is as widespread as it is very unpleasant and requires constant treatment, such as atopic eczema.
- the agent according to the invention not only do the effects of the two components add up, but two different mechanisms of action lead to the success of the therapy.
Abstract
Description
Die Erfindung betrifft ein Mittel zur Behandlung des atopischen Ekzems und anderen entzündlichen Hautkrankheiten. Die Anwendungsgebiete der Erfindung erstrecken sich auf das Gesundheitswesen, die kosmetische und die pharmazeutische Industrie.The invention relates to an agent for the treatment of atopic eczema and other inflammatory skin diseases. The fields of application of the invention extend to the health care, cosmetic and pharmaceutical industries.
Bei folgenden entzündlichen Hautkrankheiten wird als Folge der Bildung des Entzündungsmediators Leukotrien B₄ (LTB₄) in der Haut der Betroffenen die Krankheit ausgelöst bzw. unterhalten: Atopisches Ekzem (B.M. Czarnetzki et al.: Clin. Exp. Immunol. 54 (1983) 486; K. Fogh et al.: J. Allergy Clin. Immunol. 83 (1989) 68; T. Ruzicka et al: J. Invest. Dermatol. 86 (1986) 105), Psoriasis (S. Brain et al.: J. Invest. Dermatol. 83 (1984) 70; K. Fogh et al.: Arch. Dermatol. Res. 278 (1986) 173) und allergisches Kontaktekzem (R.M. Barr et al.: Br. J. Dermatol. 111 (1984) 23; H. Bisgaard et al.: Allergy 40 (1985) 417.In the following inflammatory skin diseases, the disease is triggered or maintained as a result of the formation of the inflammatory mediator leukotriene B₄ (LTB₄) in the skin of the affected person: Atopic eczema (BM Czarnetzki et al .: Clin. Exp. Immunol. 54 (1983) 486; K Fogh et al .: J. Allergy Clin. Immunol. 83 (1989) 68; T. Ruzicka et al: J. Invest. Dermatol. 86 (1986) 105), Psoriasis (S. Brain et al .: J. Invest Dermatol. 83 (1984) 70; K. Fogh et al .: Arch. Dermatol. Res. 278 (1986) 173) and allergic contact dermatitis (RM Barr et al .: Br. J. Dermatol. 111 (1984) 23; Bisgaard, H. et al .: Allergy 40 (1985) 417.
Dies impliziert, daß durch eine Hemmung der Bildung von LTB₄ in der Haut bzw. durch eine Inaktivierung von LTB₄ in der Haut die o.g. entzündlichen Hautkrankheiten behandelt werden können. Tatsächlich ist dies der Fall: Glukokortikosteroide und andere Phospholipase A2-Hemmer bzw. 5-Lipoxygenase-Hemmer sind therapiewirksam beim atopischen Ekzem, bei Psoriasis und auch beim kontaktallergischen Ekzem (Übersichten: B.C. Bastian et al.: Hautarzt 42 (1991) 417; R.D.R. Camp u. F.F. Derm: J. Invest. Dermatol. 92 (1989) 789; B.R. Allen u. S.M. Littlewood: Br. Med. J. 285 (1982) 1241).This implies that the above-mentioned inflammatory skin diseases can be treated by inhibiting the formation of LTB₄ in the skin or by inactivating LTB₄ in the skin. In fact, this is the case: glucocorticosteroids and other phospholipase A2 inhibitors or 5-lipoxygenase inhibitors are effective in treating atopic eczema, psoriasis and also contact allergic eczema (reviews: BC Bastian et al .: Dermatologist 42 (1991) 417; RDR Camp and FF Derm: J. Invest. Dermatol. 92 (1989) 789; BR Allen and SM Littlewood: Br. Med. J. 285 (1982) 1241).
Die genannten entzündungshemmenden therapeutischen Mittel haben bei äußerlicher Anwendung folgende Nachteile:
- Glukokortikosteroide: Hautatrophie, Hautalterung, Aufnahme durch die Haut und systemische Nebenwirkungen.
- Lipoxygenase-Hemmer: Toxische Nebenwirkungen bei äußerlicher Anwendung.
- Glucocorticosteroids: skin atrophy, skin aging, skin absorption and systemic side effects.
- Lipoxygenase inhibitors: Toxic side effects when used externally.
Es ist bekannt, daß bestimmte Fettsäuren die Bildung von LTB₄ hemmen:
- Gamma-Linolensäure (18:3n-6): Aus Gamma-Linolensäure entsteht 15-Hydroxy-dihomo-gamma-linolensäure. Dieses Produkt des Enzyms 15-Lipoxygenase hemmt das Enzym 5-Lipoxygenase, welche LTB₄ synthetisiert (C.C. Miller et al.: Prostaglandins 35 (1988) 917.
- Eicosapentaensäure (20:5n-6): Aus Eicosapentaensäure entsteht Leukotrien B5, daß die Bildung von LTB₄ hemmt (Lee et al.: Advances in Immunology 39 (1986) 145; Terano et al.: Prostaglandins 27 (1984) 217).
- Gamma-linolenic acid (18: 3n-6): Gamma-linolenic acid produces 15-hydroxy-dihomo-gamma-linolenic acid. This product of the enzyme 15-lipoxygenase inhibits the enzyme 5-lipoxygenase, which LTB₄ synthesizes (CC Miller et al .: Prostaglandins 35 (1988) 917.
- Eicosapentaenoic acid (20: 5n-6): Eicosapentaenoic acid produces leukotriene B5 that inhibits the formation of LTB₄ (Lee et al .: Advances in Immunology 39 (1986) 145; Terano et al .: Prostaglandins 27 (1984) 217).
Die o.g. Fettsäuren sind oftmals in diätetischen Mitteln enthalten, um die Therapie entzündlicher Hautkrankheiten zu unterstützen (C.C. Miller u. V.A. Ziboh: Biochem. Biophy. Res. Commun. 154 (1988) 967; S. Wright u. J.L. Burton: Lancet 2 (1982) 1120).The above Fatty acids are often contained in dietetic agents to support the treatment of inflammatory skin diseases (CC Miller and VA Ziboh: Biochem. Biophy. Res. Commun. 154 (1988) 967; S. Wright and JL Burton: Lancet 2 (1982) 1120).
Die DE-A-33 25 130 beschreibt pharmazeutische Zusammensetzungen zur Anwendung für die Haut auf der Basis von essentiellen Fettsäuren.DE-A-33 25 130 describes pharmaceutical compositions for use on the skin based on essential fatty acids.
Die EP-A 0 439 640 beschreibt ein Mittel zur Therapie entzündlicher Hautkrankheiten bzw. zur Abschwächung allergischer, entzündlicher Reaktionen der Haut durch äußerliche Anwendung von wasserlöslichen Magnesiumsalzen, insbesondere Magnesiumchlorid.EP-A 0 439 640 describes an agent for the therapy of inflammatory skin diseases or for the weakening of allergic, inflammatory reactions of the skin by external application of water-soluble magnesium salts, in particular magnesium chloride.
Der Erfindung liegt die Aufgabe zugrunde, der medizinischen Praxis neue Mittel in die Hand zu geben, die sich für die Therapie entzündlicher Hautkrankheiten, insbesondere des atopischen Ekzems, eignen.The object of the invention is to provide medical practice with new agents which are suitable for the therapy of inflammatory skin diseases, in particular atopic eczema.
Die Lösung dieser Aufgabe erfolgt durch Mittel zur Behandlung des atopischen Ekzems und anderen entzündlichen Hautkrankheiten bestehend aus einer äußerlich anzuwendenden Zubereitung enthaltend mindestens 0,5 Gew.-% Gamma-Linolensäure und/oder Eicosapentaensäure sowie zusätzlich 1 bis 30 Gew.-% wasserlösliche Magnesiumsalze.This object is achieved by means of the treatment of atopic eczema and other inflammatory skin diseases consisting of an externally applicable preparation containing at least 0.5% by weight of gamma-linolenic acid and / or eicosapentaenoic acid and additionally 1 to 30% by weight of water-soluble magnesium salts.
Es wurde nämlich gefunden, daß die Gamma-Linolensäure und/oder Eicosapentaensäure zusammen mit Magnesiumsalzen besonders gute und nachhaltige Wirkungen zeigen. Die erfindungsgemäßen Mittel sind somit wirksamer als die beiden Einzelkomponenten.It has been found that gamma-linolenic acid and / or eicosapentaenoic acid together with magnesium salts have particularly good and sustainable effects. The agents according to the invention are thus more effective than the two individual components.
Die Konzentration der Fettsäuren liegt in einem Bereich von 0,5 bis 50,0 Gew.-%, wobei die Fettsäuren in Trägermaterialien eingearbeitet werden, die auf die Haut aufgetragen werden können.The concentration of the fatty acids is in a range from 0.5 to 50.0% by weight, the fatty acids being incorporated into carrier materials which can be applied to the skin.
Die Konzentration des Magnesiums liegt in einem Bereich von 1,0 bis 30,0 Gew.-% im o.g. Trägermaterial.The concentration of magnesium is in the range of 1.0 to 30.0% by weight in the above. Backing material.
Das Wesen der Erfindung wird anhand einiger Ausführungsbeispiele näher beschrieben.The essence of the invention is described in more detail with the aid of a few exemplary embodiments.
Dabei wird als tierexperimentelles Modell das Modell des "Crotonöl-induzierten entzündlichen Ödems" verwendet. Es ist bekannt, daß die Entzündung bei diesem Modell primär als Folge der Wirkung von LTB₄ zustande kommt (C.B. Archer et al.: Prostaglandins 33 (1987) 799; S.E. Dahlen et al.: Proc. Natl. Acad. Sci (USA) 78 (1981) 3887; M. Katori et al.: Prostaglandins 28 (1984) 617).The model of "croton oil-induced inflammatory edema" is used as an animal experiment model. It is known that the inflammation in this model primarily results from the action of LTB ((CB Archer et al .: Prostaglandins 33 (1987) 799; SE Dahlen et al .: Proc. Natl. Acad. Sci (USA) 78 (1981) 3887; M. Katori et al .: Prostaglandins 28 (1984) 617).
Hemmung des Crotonöl-induzierten entzündlichen Ödems durch Gamma-Linolensäure, Nachtkerzenöl, Borretschöl, Rinderklauenöl und Erdnußöl allein und in Kombination mit MgCl₂ (Methodik: R.J. Dorfman: Br. J. Dermatol. 82 (Suppl. 6) (1970) 45).Inhibition of croton oil-induced inflammatory edema by gamma-linolenic acid, evening primrose oil, borage oil, bovine claw oil and peanut oil alone and in combination with MgCl₂ (method: R.J. Dorfman: Br. J. Dermatol. 82 (Suppl. 6) (1970) 45).
Die Untersuchen wurden an AB/Bln.-Mäusen (männliche Tiere, Gewicht 18 - 25 g) durchgeführt. Jede Tiergruppe bestand aus 8 Tieren.The tests were carried out on AB / Bln. Mice (male animals, weight 18-25 g). Each group of animals consisted of 8 animals.
Zur Auslösung der Entzündung (des Crotonöl-Ödems) wurde ein Ohr (rechtes äußeres und inneres Ohrblatt jedes Tieres mit je 10 µl Crotonöl (1%ig, gelöst in Aceton) behandelt. Auf das linke Ohr wurden gleichartig 10 µl Aceton aufgetragen. Eine Stunde später wurden auf das rechte Ohr 10 µl der in Tabelle 1 vorgestellten Fettsäuren allein bzw. inkorporiert in ein Trägermedium zusammen mit MgCl₂ aufgetragen. Dabei wurde das rechte Ohr mit 2,5 µg dieser Kombination bzw. mit 2,5 µg der Hydrocortison WolffR 0,5 Creme behandelt (Nr. 2 und Nr. 3 in Tabelle 1).To trigger the inflammation (the croton oil edema) one ear (right outer and inner ear leaf of each animal was treated with 10 µl croton oil (1%, dissolved in acetone). 10 µl acetone was applied to the left ear in the same way. One hour later 10 µl of the fatty acids shown in Table 1 were applied alone or incorporated into a carrier medium together with MgCl₂ to the right ear, and the right ear was treated with 2.5 µg of this combination or with 2.5 µg of the hydrocortisone Wolff R 0 , 5 cream treated (No. 2 and No. 3 in Table 1).
Fünf Stunden später wurden die Tiere durch zervikale Dislokation getötet, und es wurde aus den Ohren jedes Tieres ein Gewebestück von 8 mm ausgestanzt. Beide Gewebestücke wurden gewogen, und es wurde das Gewicht des Gewebestückes "linkes Ohr" vom Gewebestück "rechtes Ohr" subtrahiert. Die Differenz des Gewichtes entspricht dem Gewicht des "entzündlichen Ödems" (angegeben in mg in Tabelle 1).Five hours later, the animals were sacrificed by cervical dislocation and an 8 mm piece of tissue was punched out of each animal's ears. Both pieces of tissue were weighed and the weight of the piece of material "left ear" was subtracted from the piece of tissue "right ear". The difference in weight corresponds to the weight of the "inflammatory edema" (given in mg in Table 1).
Entzündungshemmende Wirkung von Nachtkerzenöl kombiniert mit MgCl₂ in einer Salbengrundlage (Nr. 3 von Tabelle 1) bei einem Patienten mit atopischem Ekzem. Nach 10tägiger äußerlicher Behandlung von Patienten mit einem atopischen Ekzem resultiert eine beschleunigte Abheilung dieser entzündlichen Dermatose (A). Im Vergleich dazu hemmte die alleinige Salbengrundlage die Entzündung nicht (B).Anti-inflammatory effects of evening primrose oil combined with MgCl₂ in an ointment base (No. 3 of Table 1) in a patient with atopic eczema. After 10 days of external treatment for patients with atopic eczema this results in an accelerated healing of this inflammatory dermatosis (A). In comparison, the sole ointment base did not inhibit inflammation (B).
Die reine Gamma-Linolensäure bzw. Öle mit einem natürlichen Anteil an Gamma-Linolensäure bzw Eicosapentaensäure sind in Konzentrationen von 0,5 % bis 50,0 % in allen Grundlagen, die auf die Haut aufgetragen werden können, diesbezüglich antientzündlich wirksam.The pure gamma-linolenic acid or oils with a natural proportion of gamma-linolenic acid or eicosapentaenoic acid are anti-inflammatory in all concentrations that can be applied to the skin in concentrations of 0.5% to 50.0%.
Diesen Zubereitungen wird 1 bis 30 Gew.-% Magnesiumchlorid beigemischt. Diese Zubereitungen sind auch im Gemisch stabil. Eine weitere, gut geeignete Salbengrundlage ist Alcoholum emulsificans non ionogenicum. Prinzipiell sind aber alle üblichen Grundlagen für Salben, Cremes, Lotionen und Gele geeignet, die auch sonst für äußerliche Anwendungen zum Einsatz kommen.1 to 30% by weight of magnesium chloride is added to these preparations. These preparations are also stable in a mixture. Another well-suited ointment base is Alcoholum emulsificans non ionogenicum. In principle, however, all the usual bases for ointments, creams, lotions and gels are suitable, which are also used for external applications.
Aus der Tabelle 2 geht hervor, daß die beiden Einzelkomponenten Magnesiumchlorid und Nachtkerzenöl für sich alleine in der gleichen Salbengrundlage jeweils nur eine prozentuale Hemmung des entzündlichen Ödems von 37 bzw. 30,6 % zeigen. Die erfindungsgemäße Kombination dieser beiden Wirkstoffe zeigt aber eine prozentuale Hemmung von 58 % und erzielt damit erstmals eine vergleichbar gute Wirkung wie Hydrocortison. Es war nicht vorhersehbar, daß es möglich ist, mit der Kombination der zwei natürlichen und ungefährlichen Wirkstoffe bei einer so weit verbreiteten und dennoch sehr unangenehmen und ständig behandlungsbedürftigen Krankheit, wie die atopischen Ekzeme, zu so guten Ergebnissen zu kommen. Offensichtlich addieren sich bei dem erfindungsgemäßen Mittel nicht nur die Wirkungen der beiden Komponenten, sondern führen zwei unterschiedliche Wirkmechanismen zu den Therapieerfolgen.
Claims (6)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4238869 | 1992-11-18 | ||
| DE4238869A DE4238869C2 (en) | 1992-11-18 | 1992-11-18 | Agents for the treatment of atopic eczema and other inflammatory skin diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0598365A1 true EP0598365A1 (en) | 1994-05-25 |
| EP0598365B1 EP0598365B1 (en) | 1996-09-11 |
Family
ID=6473154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP93118411A Expired - Lifetime EP0598365B1 (en) | 1992-11-18 | 1993-11-13 | Agent for the treatment of an atopic eczema and other inflammatory skin diseases |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0598365B1 (en) |
| AT (1) | ATE142491T1 (en) |
| DE (2) | DE4238869C2 (en) |
| DK (1) | DK0598365T3 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997035570A1 (en) * | 1996-03-26 | 1997-10-02 | Beiersdorf Ag | Use of unsaturated monocarboxylic acids against superinfections |
| FR2765482A1 (en) * | 1997-07-07 | 1999-01-08 | Oreal | USE OF Y-LINOLENIC ACID TO PREVENT OXIDATIVE STRESS |
| US6107334A (en) * | 1998-02-23 | 2000-08-22 | Wake Forest University | Dietary control of arachidonic acid metabolism |
| WO2005034967A1 (en) * | 2003-10-10 | 2005-04-21 | Hans-Joachim Lach | Pharmaceutical or cosmetic compositions for treating skin |
| US7138431B1 (en) | 1998-02-23 | 2006-11-21 | Wake Forest University | Dietary control of arachidonic acid metabolism |
| WO2007020479A2 (en) * | 2005-08-19 | 2007-02-22 | York Pharma Plc | Pharmaceutical compositions comprising metals for modulating epithelial cell-to-cell adhesion |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| CN109157428A (en) * | 2012-09-06 | 2019-01-08 | Af免疫有限公司 | Cosmetic composition and production and preparation method thereof including eicosapentaenoic acid free acid and gamma-Linolenic acid free acid |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| SG11201610207WA (en) | 2014-06-04 | 2017-01-27 | Dignity Sciences Ltd | Pharmaceutical compositions comprising dgla and use of same |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885157A (en) * | 1987-02-13 | 1989-12-05 | Fiaschetti Mary G | Dermal cosmetic composition and applications therefor |
| EP0391218A2 (en) * | 1989-04-04 | 1990-10-10 | Beiersdorf Aktiengesellschaft | Agent for the atopy prophylaxis |
| WO1990014824A1 (en) * | 1988-01-14 | 1990-12-13 | Anders Frithz | Use of essential fatty acids for the preparation of a drug for the treatment of eczema |
| EP0432700A2 (en) * | 1987-08-25 | 1991-06-19 | Efamol Holdings Plc | Use of lithium compounds for the treatment of combination skin |
| EP0439640A1 (en) * | 1990-01-29 | 1991-08-07 | WOGEPHARM GmbH | Method for preparing agents for the therapy of skin diseases |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2548021B1 (en) * | 1983-06-29 | 1986-02-28 | Dick P R | PROLONGED AND CONTINUOUS DERMAL PHARMACEUTICAL COMPOSITIONS BASED ON ESSENTIAL FATTY ACIDS |
| DE4042437A1 (en) * | 1990-07-18 | 1992-06-11 | Braun Melsungen Ag | Topical compsn. for treating burns - contg. omega-3-fatty acid esp. eicosa-penta:enoic acid as fish oil component, providing rapid healing |
-
1992
- 1992-11-18 DE DE4238869A patent/DE4238869C2/en not_active Expired - Fee Related
-
1993
- 1993-11-13 AT AT93118411T patent/ATE142491T1/en active
- 1993-11-13 DK DK93118411.3T patent/DK0598365T3/da active
- 1993-11-13 DE DE59303744T patent/DE59303744D1/en not_active Expired - Fee Related
- 1993-11-13 EP EP93118411A patent/EP0598365B1/en not_active Expired - Lifetime
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885157A (en) * | 1987-02-13 | 1989-12-05 | Fiaschetti Mary G | Dermal cosmetic composition and applications therefor |
| EP0432700A2 (en) * | 1987-08-25 | 1991-06-19 | Efamol Holdings Plc | Use of lithium compounds for the treatment of combination skin |
| WO1990014824A1 (en) * | 1988-01-14 | 1990-12-13 | Anders Frithz | Use of essential fatty acids for the preparation of a drug for the treatment of eczema |
| EP0391218A2 (en) * | 1989-04-04 | 1990-10-10 | Beiersdorf Aktiengesellschaft | Agent for the atopy prophylaxis |
| EP0439640A1 (en) * | 1990-01-29 | 1991-08-07 | WOGEPHARM GmbH | Method for preparing agents for the therapy of skin diseases |
Non-Patent Citations (1)
| Title |
|---|
| Dialog Information Services, File 73, Embase 1974-1994, Accession Number: 5119554: J. Holistic Med. vol. 3/2, 1981, pages 118-139, D.F. Horrobin: The importance of gamma-linolenic * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997035570A1 (en) * | 1996-03-26 | 1997-10-02 | Beiersdorf Ag | Use of unsaturated monocarboxylic acids against superinfections |
| FR2765482A1 (en) * | 1997-07-07 | 1999-01-08 | Oreal | USE OF Y-LINOLENIC ACID TO PREVENT OXIDATIVE STRESS |
| EP0891773A1 (en) * | 1997-07-07 | 1999-01-20 | L'oreal | Use of gamma-linolenic acid for preventing oxydative stress |
| US8247449B2 (en) | 1998-02-23 | 2012-08-21 | Wake Forest University | Methods and compositions for the treatment of asthma |
| US6107334A (en) * | 1998-02-23 | 2000-08-22 | Wake Forest University | Dietary control of arachidonic acid metabolism |
| US7138431B1 (en) | 1998-02-23 | 2006-11-21 | Wake Forest University | Dietary control of arachidonic acid metabolism |
| WO2005034967A1 (en) * | 2003-10-10 | 2005-04-21 | Hans-Joachim Lach | Pharmaceutical or cosmetic compositions for treating skin |
| WO2007020479A2 (en) * | 2005-08-19 | 2007-02-22 | York Pharma Plc | Pharmaceutical compositions comprising metals for modulating epithelial cell-to-cell adhesion |
| EP1938817A3 (en) * | 2005-08-19 | 2008-12-03 | York Pharma PLC | Pharmaceutical compositions comprising metals for modulating epithelial cell-to-cell adhesion |
| JP2009504723A (en) * | 2005-08-19 | 2009-02-05 | ヨーク・ファーマ・ピーエルシー | Improvements in pharmaceutical composition |
| WO2007020479A3 (en) * | 2005-08-19 | 2007-05-24 | York Pharma Plc | Pharmaceutical compositions comprising metals for modulating epithelial cell-to-cell adhesion |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| CN109157428A (en) * | 2012-09-06 | 2019-01-08 | Af免疫有限公司 | Cosmetic composition and production and preparation method thereof including eicosapentaenoic acid free acid and gamma-Linolenic acid free acid |
Also Published As
| Publication number | Publication date |
|---|---|
| DK0598365T3 (en) | 1997-02-24 |
| DE4238869C2 (en) | 1994-09-08 |
| DE59303744D1 (en) | 1996-10-17 |
| DE4238869A1 (en) | 1994-05-19 |
| ATE142491T1 (en) | 1996-09-15 |
| EP0598365B1 (en) | 1996-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2721831A1 (en) | ANTI-INFLAMMATORY, TOPIC MEDICINAL PREPARATIONS | |
| DE2818553A1 (en) | COMPOSITION FOR THE TREATMENT OF PROLIFERATIVE SKIN DISEASES | |
| DE2046119A1 (en) | Middle) to treat acne | |
| DE4238869C2 (en) | Agents for the treatment of atopic eczema and other inflammatory skin diseases | |
| DE2947742A1 (en) | (BETA) -CYCLODEXTRIN AS AN ANTI-ACNE AGENT | |
| DE69825279T2 (en) | USE OF GLUCOSAMINE AND GLUCOSAMINE DERIVATIVES FOR THE FAST RELIEF OF JUCKREIZ OR LOCALIZED PAIN | |
| EP0936865A1 (en) | Stable aqueous formulation of 3-(n-butylacetamino)-propionic acid ethyl ester | |
| EP0439640B1 (en) | Method for preparing agents for the therapy of skin diseases | |
| EP0325628B1 (en) | Agent containing salicylic acid for treating lepidosis | |
| EP0467116B1 (en) | Dermatological compositions containing cis-urocanic acid | |
| EP1955591A1 (en) | Agent for cleaning and antimicrobial treatment of skin | |
| DE2447627B2 (en) | ANTIMICROBIAL PREPARATION | |
| EP0129014A1 (en) | Deodorizing cosmetic composition | |
| DE3402877C2 (en) | ||
| EP0432354B1 (en) | Bath additive and its use | |
| DE3049038C2 (en) | ||
| DE1492023C3 (en) | Skin care products | |
| DE3417234A1 (en) | Skin care composition containing a combination of bakuchiol and pyridine aldehyde | |
| DE1617855C (en) | Therapeutic agent for treating acne | |
| WO1996012504A1 (en) | Oil-in-water formulation for topical application | |
| DE1617855B1 (en) | Therapeutic agent for the treatment of acne | |
| WO1998023245A2 (en) | Preservative containing 1,6-hexanediol | |
| DE2922012A1 (en) | PHARMACEUTICAL PREPARATIONS AND THEIR USE IN WOUND TREATMENT | |
| DE102004034747B4 (en) | Ointment preparation suitable for neurodermitic skin diseases | |
| WO2021099555A1 (en) | Cosmetic preparation containing anisic acid and levulinic acid, having selective antimicriobial effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19940114 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT CH DE DK FR GB IT LI NL SE |
|
| 17Q | First examination report despatched |
Effective date: 19940909 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DIEZEL, W. PROF. DR. |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT CH DE DK FR GB IT LI NL SE |
|
| REF | Corresponds to: |
Ref document number: 142491 Country of ref document: AT Date of ref document: 19960915 Kind code of ref document: T |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: SCHMAUDER & WANN PATENTANWALTSBUERO, INHABER KLAUS |
|
| REF | Corresponds to: |
Ref document number: 59303744 Country of ref document: DE Date of ref document: 19961017 |
|
| ITF | It: translation for a ep patent filed |
Owner name: ING. C. GREGORJ S.P.A. |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19961130 Ref country code: CH Effective date: 19961130 |
|
| GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 19961209 |
|
| ET | Fr: translation filed | ||
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed | ||
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20001122 Year of fee payment: 8 Ref country code: DK Payment date: 20001122 Year of fee payment: 8 Ref country code: AT Payment date: 20001122 Year of fee payment: 8 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20001123 Year of fee payment: 8 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20011113 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20011113 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20011114 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20011129 Year of fee payment: 9 |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20020129 Year of fee payment: 9 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020601 |
|
| EUG | Se: european patent has lapsed |
Ref document number: 93118411.3 |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
| NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20020601 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20021113 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20021223 Year of fee payment: 10 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030731 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040602 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20051113 |